Sellas Life Sciences Group Inc

A decisive support failure below the 9/20/50 EMAs signals medium-term bearish acceleration despite a still-intact long-term uptrend above the 200 DMA. Oversold conditions warrant caution against chasing the decline, and under a Speculative mandate, the preferred approach is to defer short entry until a pullback into the broken support zone offers a clear rejection setup.

• ↑Galinpepimut-S (GPS) advancing toward Phase 3 readout with strong early efficacy data
• ↑$138.3 M cash and equivalents support late-stage trials through 2026
• ↓Q2 net loss widened to $9.6 M, R&D spend rose to $6.3 M